Replimune Group, Inc. REPL
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 2 Hold · 1 Sell (8 analysts)
- Avg. Price Target
- $16.33 (-9.7% downside)
Key Stats
- Today's Range
- $17.75 – $18.40
- 50-Day Range
- $10.67 – $18.40
- 52-Week Range
- $1.50 – $18.40
- Volume
- 368K shs
- Average Volume
- 2.37 million shs
- Market Cap
- $1.67 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.03%
- Days to Cover
- 1.00
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Related Stocks
Compare head-to-head: REPL vs AMGN·REPL vs MRNA·REPL vs HALO·REPL vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.